Trial Profile
A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Bococizumab (Primary)
- Indications Dyslipidaemias; Hyperlipidaemia
- Focus Registrational; Therapeutic Use
- Acronyms SPIRE-HR
- Sponsors Pfizer
- 16 Sep 2019 Results assessing cross-reactivity between anti-bococizumab antibodies and other anti-PCSK9 monoclonal antibodies by using data from this study published in the BioDrugs.
- 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
- 17 Mar 2017 Results of a pooled analysis from SPIRE-HR, SPIRE-LDL, SPIRE-LDL, SPIRE-LL, SPIRE-SI and SPIRE-AI studies (n=4449), published in the New England Journal of Medicine.